ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 69 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,438,000 | -57.6% | 250,000 | 0.0% | 1.31% | -35.1% |
| Q3 2018 | $3,390,000 | +14.3% | 250,000 | 0.0% | 2.02% | +18.9% |
| Q2 2018 | $2,965,000 | +5.7% | 250,000 | 0.0% | 1.69% | -2.9% |
| Q1 2018 | $2,805,000 | +68.0% | 250,000 | 0.0% | 1.74% | +44.1% |
| Q4 2017 | $1,670,000 | -18.3% | 250,000 | 0.0% | 1.21% | -14.5% |
| Q3 2017 | $2,045,000 | +81.8% | 250,000 | 0.0% | 1.42% | +58.2% |
| Q2 2017 | $1,125,000 | -18.2% | 250,000 | 0.0% | 0.90% | -12.6% |
| Q1 2017 | $1,375,000 | +37.1% | 250,000 | 0.0% | 1.02% | +22.2% |
| Q4 2016 | $1,003,000 | -43.1% | 250,000 | 0.0% | 0.84% | -50.4% |
| Q3 2016 | $1,763,000 | -13.3% | 250,000 | 0.0% | 1.69% | -20.6% |
| Q2 2016 | $2,033,000 | +0.2% | 250,000 | 0.0% | 2.13% | +13.0% |
| Q1 2016 | $2,028,000 | -32.7% | 250,000 | 0.0% | 1.88% | +3.6% |
| Q4 2015 | $3,013,000 | – | 250,000 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $5,165,000 | 4.93% |
| Long Focus Capital Management, LLC | 4,429,491 | $9,125,000 | 1.17% |
| Endurant Capital Management LP | 2,160,890 | $4,451,000 | 1.17% |
| NEA Management Company, LLC | 17,082,611 | $35,190,000 | 1.02% |
| Matrix Capital Management Company, LP | 38,974,185 | $80,287,000 | 0.96% |
| Key Client Fiduciary Advisors, LLC | 420,447 | $866,000 | 0.68% |
| ACT CAPITAL MANAGEMENT, LLC | 90,000 | $185,000 | 0.20% |
| DAFNA Capital Management LLC | 351,064 | $723,000 | 0.19% |
| PFM Health Sciences, LP | 2,374,674 | $4,892,000 | 0.18% |
| Rock Springs Capital Management LP | 2,297,194 | $4,732,000 | 0.12% |